newsfilter
← Latest News
Business Wire·

Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update

-- TAZVERIK® (tazemetostat) Net Product Revenues of $5.2 Million; End User Demand Grew 22% -- -- Received $25 Million Upfront Payment from HUTCHMED License Agreement -- -- SYMPHONY-1 (EZH-302) Preparing for Phase 3 Initiation; SETD2 Phase 1/1b St